聚ADP核糖聚合酶
合成致死
DNA修复
PARP抑制剂
机制(生物学)
抗药性
聚合酶
同源重组
医学
癌症研究
DNA
生物
遗传学
哲学
认识论
作者
Xiaoyu Fu,Ping Li,Qi Zhou,Ruyuan He,Guannan Wang,Shiya Zhu,Amir Bagheri,Gary M. Kupfer,Huadong Pei,Juanjuan Li
标识
DOI:10.1016/j.gendis.2023.02.014
摘要
PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous recombination (HR) repair deficiency, innate and acquired resistance to PARPi is a main challenge in the clinic. In this review, we mainly discussed the underlying mechanisms of PARPi resistance and summarized the promising solutions to overcome PARPi resistance, aiming at extending PARPi application and improving patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI